110 related articles for article (PubMed ID: 27219508)
1. Increased expression of brother of the regulator of imprinted sites in peripheral blood neutrophils is associated with both benign and malignant breast lesions.
El-Sharkawy NM; Radwan WM; Essa ES; Kandeel EZ; Abd El-Fattah EK; Kandil SH; Kamel AM
Cytometry B Clin Cytom; 2017 Sep; 92(5):355-360. PubMed ID: 27219508
[TBL] [Abstract][Full Text] [Related]
2. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.
D'Arcy V; Pore N; Docquier F; Abdullaev ZK; Chernukhin I; Kita GX; Rai S; Smart M; Farrar D; Pack S; Lobanenkov V; Klenova E
Br J Cancer; 2008 Feb; 98(3):571-9. PubMed ID: 18195709
[TBL] [Abstract][Full Text] [Related]
3. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
4. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract][Full Text] [Related]
5. Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.
Akhtar MS; Akhter N; Talat A; Alharbi RA; Sindi AAA; Klufah F; Alyahyawi HE; Alruwetei A; Ahmad A; Zamzami MA; Deo S; Husain SA; Badi OA; Khan MJ
Oncotarget; 2023 May; 14():528-541. PubMed ID: 37235839
[TBL] [Abstract][Full Text] [Related]
6. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
7. The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis.
D'Arcy V; Abdullaev ZK; Pore N; Docquier F; Torrano V; Chernukhin I; Smart M; Farrar D; Metodiev M; Fernandez N; Richard C; Delgado MD; Lobanenkov V; Klenova E
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5978-86. PubMed ID: 17062669
[TBL] [Abstract][Full Text] [Related]
8. BORIS and CTCF are overexpressed in squamous intraepithelial lesions and cervical cancer.
Velázquez-Hernández N; Reyes-Romero MA; Barragán-Hernández M; Guerrero-Romero F; Rodríguez-Moran M; Aguilar-Durán M; Lazalde Medina B
Genet Mol Res; 2015 Jun; 14(2):6094-100. PubMed ID: 26125810
[TBL] [Abstract][Full Text] [Related]
9. Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.
Dougherty CJ; Ichim TE; Liu L; Reznik G; Min WP; Ghochikyan A; Agadjanyan MG; Reznik BN
Biochem Biophys Res Commun; 2008 May; 370(1):109-12. PubMed ID: 18355444
[TBL] [Abstract][Full Text] [Related]
10. Expression of the cancer-testis antigen BORIS correlates with prostate cancer.
Cheema Z; Hari-Gupta Y; Kita GX; Farrar D; Seddon I; Corr J; Klenova E
Prostate; 2014 Feb; 74(2):164-76. PubMed ID: 24123052
[TBL] [Abstract][Full Text] [Related]
11. [Preparation of the monoclonal antibodies against human BORIS and the expression pattern of BORIS in normal and diseased human mammary tissues].
Zhou XC; Song CJ; Wang X; Tian Y; Jin BQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Apr; 23(4):353-5. PubMed ID: 17428394
[TBL] [Abstract][Full Text] [Related]
12. The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer.
Klenova EM; Morse HC; Ohlsson R; Lobanenkov VV
Semin Cancer Biol; 2002 Oct; 12(5):399-414. PubMed ID: 12191639
[TBL] [Abstract][Full Text] [Related]
13. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
Kholmanskikh O; Loriot A; Brasseur F; De Plaen E; De Smet C
Int J Cancer; 2008 Feb; 122(4):777-84. PubMed ID: 17957795
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
15. The cancer-testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells.
Tiffen JC; Bailey CG; Marshall AD; Metierre C; Feng Y; Wang Q; Watson SL; Holst J; Rasko JE
Int J Cancer; 2013 Oct; 133(7):1603-13. PubMed ID: 23553099
[TBL] [Abstract][Full Text] [Related]
16. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
17. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
18. BORIS in human cancers -- a review.
Martin-Kleiner I
Eur J Cancer; 2012 Apr; 48(6):929-35. PubMed ID: 22019212
[TBL] [Abstract][Full Text] [Related]
19. The function of brother of the regulator of imprinted sites in cancer development.
Zhou S; Li L; Zhang M; Qin Y; Li B
Cancer Gene Ther; 2023 Feb; 30(2):236-244. PubMed ID: 36376421
[TBL] [Abstract][Full Text] [Related]
20. A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
Yoon SL; Roh YG; Chu IS; Heo J; Kim SI; Chang H; Kang TH; Chung JW; Koh SS; Larionov V; Leem SH
Exp Mol Med; 2016 Jul; 48(7):e246. PubMed ID: 27416782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
